抗ヒスタミン薬の世界市場

抗ヒスタミン薬の世界市場は2030年までに3億5,720万米ドルに達する見込み

2024年に2億7,410万米ドルと推定される抗ヒスタミン薬の世界市場は、分析期間2024-2030年にCAGR 4.5%で成長し、2030年には3億5,720万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるH-1ブロッカーは、CAGR5.5%を記録し、分析期間終了時には2億2,740万米ドルに達すると予測されます。H-2ブロッカーセグメントの成長率は、分析期間中CAGR 3.0%と推定されます。

米国市場は7,470万米ドルと推定、中国はCAGR 8.4％で成長予測

米国の抗ヒスタミン薬市場は、2024年に7,470万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 8.4%で推移し、2030年には予測市場規模7,470万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.8％と3.6％と予測されています。欧州では、ドイツがCAGR 2.6%で成長すると予測されています。

世界の抗ヒスタミン薬市場- 主要動向と促進要因まとめ

なぜ抗ヒスタミン薬はアレルギー性、炎症性、過敏症の管理に不可欠なのか？

抗ヒスタミン薬は、アレルギー性鼻炎、蕁麻疹、結膜炎、アナフィラキシー、その他の過敏反応に関連する症状を軽減または予防するために、ヒスタミン受容体に拮抗することによって機能し、アレルギー性疾患の管理において基礎的な役割を果たしています。H1またはH2受容体のヒスタミン活性を阻害することにより、これらの薬剤はかゆみ、腫れ、鼻づまり、じんましんなどの症状を緩和し、急性および慢性のアレルギー性疾患において迅速な症状コントロールを提供します。その有用性は、自己限定的な季節性アレルギーから、より持続的で内科的に管理される皮膚疾患や呼吸器疾患まで多岐にわたる。

第一世代の抗ヒスタミン薬は有効ではあるが、血液脳関門を通過するため鎮静作用や中枢神経系への影響を伴う。対照的に、ロラタジン、フェキソフェナジン、レボセチリジンなどの第2および第3世代の抗ヒスタミン薬は、受容体選択性が高く、作用時間が長く、鎮静作用が少ないです。これらの新しい薬剤は、特にアレルギー性鼻炎やアトピー性皮膚炎のような日常的に使用される場面において、認知障害や眠気を伴わずに患者のQOLを維持することを可能にし、長期的な治療に望ましい選択肢となっています。

抗ヒスタミン薬はアレルギー治療以外にも、アナフィラキシー、乗り物酔い、不眠症、化学療法に伴う吐き気などの補助的治療など、より幅広い治療薬としての役割が模索されています。H1抗ヒスタミン薬の中には、自己免疫疾患や炎症性疾患におけるサイトカイン活性を調節する適応外の可能性を示すものもあります。一方、H2受容体拮抗薬は、プロトンポンプ阻害薬（PPI）の取り込みによりその重要性は低下しているもの、GERD、消化性潰瘍疾患、ヒスタミンが介在する消化管過敏症などの治療に依然として関連しています。このような幅広い適用範囲により、抗ヒスタミン薬の臨床的・商業的意義は、複数の治療経路にまたがって強化され続けています。

製剤の進歩とデリバリーの革新は、抗ヒスタミン薬アクセシビリティとコンプライアンスをどのように向上させているか？

最近の製剤の進歩により、抗ヒスタミン薬治療の薬物動態、忍容性、利便性が向上しています。長時間作用型の1日1回経口投与製剤は、現在広く利用できるようになり、錠剤の負担を軽減し、慢性アレルギー患者の服薬アドヒアランスを高めています。口腔内崩壊錠、チュアブル製剤、液状懸濁液は小児および老年患者のコンプライアンスをサポートし、配合剤（抗ヒスタミン薬と充血除去薬など）は上気道アレルギーの管理においてより幅広い症状コントロールを提供します。

アゼラスチンのような経鼻抗ヒスタミン薬は、全身への曝露を最小限に抑えながら、迅速かつ局所的な症状緩和を必要とする患者に対して、普及しつつあります。これらは、特に経鼻コルチコステロイドと併用した場合に、アレルギー性鼻炎における鼻づまりや鼻漏に有効です。局所用抗ヒスタミン薬は、そう痒症、虫刺され、アトピー性皮膚炎などの皮膚科領域にも使用され、全身性の副作用を伴わずに炎症部位で迅速に症状をコントロールすることができます。

さらに、アナフィラキシーやアレルギー性薬物反応の緊急治療など、急性期医療の現場では注射薬や静脈内抗ヒスタミン薬が使用され続けています。治療域を拡大し、症状の再発を抑えるために、徐放性製剤やデュアルメカニズム製剤（デュアルH1/H2ブロッカーや抗ヒスタミン薬-マスト細胞安定化剤のハイブリッド製剤など）の進歩が追求されています。患者中心のケアモデルが拡大するにつれ、抗ヒスタミン薬市場の持続可能性と成長には、使いやすさ、迅速な発症、最小限の副作用をサポートするデリバリーシステムが不可欠となっています。

抗ヒスタミン薬の需要成長を牽引している適応症と世界地域は？

アレルギー性鼻炎が抗ヒスタミン薬の主要な適応症であり、慢性蕁麻疹、アトピー性皮膚炎、結膜炎がそれに続いています。環境汚染、都市化、ライフスタイルの変化によって、アレルギー疾患の世界の有病率が上昇していることが、処方薬と一般用医薬品（OTC）の両セグメントにおける抗ヒスタミン薬治療の需要拡大に寄与しています。特に呼吸器系アレルギーは、花粉曝露の増加、室内アレルゲンの増加、気候の変動などが原因で、特に都市部の集団で急増しています。

小児アレルギー治療は急成長している分野であり、良好な安全性プロファイル、即効性、非ステロイド性という点から抗ヒスタミン薬が好まれています。小児の季節性・通年性アレルギーと、鎮静作用がなく小児にやさしい製剤を求める親の要望が、製品開拓とマーケティング戦略に影響を与えています。これと並行して、ポリファーマシー（多剤併用）のリスクを抱える高齢者層は、慢性アレルギー疾患や皮膚疾患における安全な長期使用のために、第2世代の低相互作用抗ヒスタミン薬に嗜好を移しつつあります。

地域的には、北米と欧州が、確立されたヘルスケアシステム、アレルギー診断の普及、強力なOTC小売網により、抗ヒスタミン薬の消費を支配しています。しかし、アジア太平洋地域は、中国、インド、東南アジアにおけるアレルギー発症率の上昇、ヘルスケアへのアクセスの改善、一般市民の意識の高まりに支えられ、急成長を遂げています。組織小売の拡大、医薬品普及率の上昇、開発途上地域における診断率の向上は、臨床と消費者の両面で抗ヒスタミン剤の世界の需要動向をさらに強めています。

規制の再分類、市場競争、OTCの拡大は市場力学をどのように形成しているか？

抗ヒスタミン薬の大部分は、その強力な安全性プロファイルと広範な使用を反映し、成熟市場では処方箋のみからOTCへと移行しています。規制による再分類は、消費者のアクセスを拡大し、小売販売を強化し、軽度から中等度のアレルギー症状に対するセルフメディケーションを可能にしました。この傾向は市場規模を拡大する一方、価格競争を激化させ、コモディティ化したOTC市場の中でシェアを維持するためには、強力なブランド戦略、製剤の差別化、消費者直結型のマーケティング戦略が必要となります。

同時に、ジェネリック医薬品の浸食は、特にレガシーな第一世代や第二世代の分子にとって、根強い課題となっています。ブランドメーカーは、製品ラインの拡張、小児専用処方、コンビネーションパック、患者ロイヤルティプログラムなどで対応し、市場でのポジショニングを維持しています。また、デジタルヘルスプラットフォームやテレヘルスの統合に投資し、OTC抗ヒスタミン薬の販売と個別化された症状管理やアレルギー専門医の紹介を組み合わせている企業もあります。

一方、乳幼児、妊婦、心血管系の合併症を持つ患者などの脆弱な集団における抗ヒスタミン薬の安全性に関する規制当局の監視は、添付文書の更新、投与ガイドラインの改訂、ファーマコビジランスへの新たな注力を促しています。保健当局が安全性と有効性の要件を強化する中、メーカーは、規制市場と準規制市場の両方で競争力を維持するために、強固な臨床エビデンス、市販後調査、世界コンプライアンスの枠組みに投資する必要があります。

抗ヒスタミン薬市場の成長を促進する要因は何か？

抗ヒスタミン薬市場は、世界のアレルギー疾患負担の増加、症状に焦点を当てた治療への嗜好の高まり、消費者管理医療へのシフトに牽引され、一貫して拡大しています。成長を可能にする主な要因としては、OTCの利用可能性の拡大、良好な安全性プロファイル、患者固有のニーズに対応するデリバリー・フォーマットの継続的な革新などが挙げられます。抗ヒスタミン薬は、呼吸器、皮膚、消化器、急性期医療など幅広い治療領域で使用されているため、今後も市場の重要性が維持されるであろう。

製剤の進歩、各地域への市場浸透、セルフケアの動向との合致が、ブランド薬とジェネリック医薬品の両分野におけるカテゴリーの成長を支えています。非鎮静性、即効性、持続時間の長い抗ヒスタミン薬への需要が高まる中、メーカーは飽和しつつある小売チャネルで競争力を維持するため、差別化されたライフサイクルに最適化されたポートフォリオに注力しています。同時に、デジタルヘルスツールやAIによるアレルギー追跡により、抗ヒスタミン薬を積極的な疾病管理と結びつける新たな機会が生まれつつあります。

今後、市場の進化は、消費者の入手しやすさ、臨床的有効性、規制上の安全性のバランスにメーカーがいかに対処するかによって形作られるであろう。環境要因が強まり、患者の期待が進化する中、抗ヒスタミン薬は現代のアレルギー・過敏症症状コントロールの要としての役割を維持できるだろうか。

セグメント

製品タイプ（H-1ブロッカー、H-2ブロッカー）、投与経路（経口剤、非経口剤、局所剤）、適応症（アレルギー、蕁麻疹、皮膚炎、その他の適応症）、流通チャネル（病院薬局、小売薬局、ドラッグストア、オンライン薬局、その他の流通チャネル）

調査対象企業の例（注目の44社）

• Ajanta Pharma Limited
• Almirall S.A.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• CVS Health Corporation
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd.
• Hetero Drugs Ltd.
• Innate Pharma S.A.
• Johnson & Johnson
• Jubilant Pharma Limited
• Menarini Group
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Olpha JSC

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Antihistamine Market to Reach US$357.2 Million by 2030

The global market for Antihistamine estimated at US$274.1 Million in the year 2024, is expected to reach US$357.2 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. H-1 Blockers, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$227.4 Million by the end of the analysis period. Growth in the H-2 Blockers segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$74.7 Million While China is Forecast to Grow at 8.4% CAGR

The Antihistamine market in the U.S. is estimated at US$74.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$74.7 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Antihistamine Market - Key Trends & Drivers Summarized

Why Are Antihistamines Critical to Managing Allergic, Inflammatory, and Hypersensitivity Conditions?

Antihistamines play a foundational role in the management of allergic disorders, functioning by antagonizing histamine receptors to reduce or prevent symptoms associated with allergic rhinitis, urticaria, conjunctivitis, anaphylaxis, and other hypersensitivity reactions. By blocking histamine activity at H1 or H2 receptors, these drugs provide relief from itching, swelling, nasal congestion, and hives-offering rapid symptomatic control in both acute and chronic allergic conditions. Their utility spans across self-limiting seasonal allergies to more persistent, medically managed dermatologic and respiratory disorders.

First-generation antihistamines, though effective, are associated with sedation and central nervous system effects due to their ability to cross the blood-brain barrier. In contrast, second- and third-generation antihistamines such as loratadine, fexofenadine, and levocetirizine offer greater receptor selectivity and longer duration of action with minimal sedation. These newer agents have become the preferred choice for long-term therapy, enabling patients to maintain quality of life without cognitive impairment or drowsiness, particularly in daily-use scenarios such as allergic rhinitis or atopic dermatitis.

Beyond allergy management, antihistamines are being explored for broader therapeutic roles, including adjunctive treatment in anaphylaxis, motion sickness, insomnia, and nausea associated with chemotherapy. Some H1 antihistamines also show off-label potential in modulating cytokine activity in autoimmune and inflammatory disorders. Meanwhile, H2 receptor antagonists, though declining in prominence due to proton pump inhibitor (PPI) uptake, remain relevant in treating conditions like GERD, peptic ulcer disease, and histamine-mediated gastrointestinal hypersensitivity. This wide application scope continues to reinforce the clinical and commercial relevance of antihistamines across multiple care pathways.

How Are Formulation Advances and Delivery Innovations Enhancing Antihistamine Accessibility and Compliance?

Recent advances in drug formulation have improved the pharmacokinetics, tolerability, and convenience of antihistamine therapies. Long-acting, once-daily oral formulations are now widely available, reducing pill burden and enhancing adherence in chronic allergy sufferers. Orally disintegrating tablets, chewable forms, and liquid suspensions support pediatric and geriatric patient compliance, while combination products (e.g., antihistamines with decongestants) offer broader symptom control in upper respiratory allergy management.

Intranasal antihistamines such as azelastine are gaining ground for patients requiring rapid, localized symptom relief with minimal systemic exposure. These are particularly effective for nasal congestion and rhinorrhea in allergic rhinitis, especially when used in combination with intranasal corticosteroids. Topical antihistamines are also used for dermatologic applications, including pruritus, insect bites, and atopic dermatitis, offering fast symptom control at the site of inflammation without systemic side effects.

Additionally, injectable and intravenous antihistamines continue to be used in acute care settings, including emergency treatment of anaphylaxis and allergic drug reactions. Advances in extended-release and dual-mechanism formulations (such as dual H1/H2 blockers or antihistamine-mast cell stabilizer hybrids) are being pursued to expand the therapeutic window and reduce recurrence of symptoms. As patient-centric care models expand, delivery systems that support ease of use, rapid onset, and minimal side effects are becoming critical to antihistamine market sustainability and growth.

Which Indications and Global Regions Are Driving Antihistamine Demand Growth?

Allergic rhinitis remains the leading indication for antihistamine use, followed by chronic urticaria, atopic dermatitis, and conjunctivitis. The rising global prevalence of allergic diseases-driven by environmental pollution, urbanization, and changing lifestyle patterns-is contributing to growing demand for antihistamine therapy across both prescription and over-the-counter (OTC) segments. Respiratory allergies, in particular, are surging due to increased pollen exposure, indoor allergens, and climate variability, especially in urban populations.

Pediatric allergy treatment is a rapidly growing segment, where antihistamines are preferred for their favorable safety profile, rapid action, and non-steroidal nature. Seasonal and perennial allergies in children, coupled with parental demand for non-sedating, child-friendly formulations, are influencing product development and marketing strategies. In parallel, elderly populations with polypharmacy risks are shifting preference toward second-generation, low-interaction antihistamines for safe long-term use in chronic allergic and skin conditions.

Geographically, North America and Europe dominate antihistamine consumption due to well-established healthcare systems, widespread allergy diagnostics, and strong OTC retail networks. However, Asia-Pacific is experiencing the fastest growth, supported by rising allergy incidence, improved access to healthcare, and increasing public awareness in China, India, and Southeast Asia. The expansion of organized retail, growing pharmaceutical penetration, and higher diagnosis rates in developing regions are further reinforcing the global demand trajectory for antihistamines in both clinical and consumer settings.

How Are Regulatory Reclassifications, Market Competition, and OTC Expansion Reshaping Market Dynamics?

A significant portion of antihistamines has transitioned from prescription-only to OTC status in mature markets, reflecting their strong safety profile and widespread use. Regulatory reclassification has expanded consumer access, bolstered retail sales, and enabled self-medication for mild to moderate allergy symptoms. While this trend enhances market volume, it also intensifies price competition and necessitates strong branding, formulation differentiation, and direct-to-consumer marketing strategies to maintain share in a commoditized OTC landscape.

At the same time, generic erosion is a persistent challenge, particularly for legacy first- and second-generation molecules. Branded manufacturers are responding with product line extensions, pediatric-specific formulations, combination packs, and patient loyalty programs to retain market positioning. Some companies are also investing in digital health platforms and telehealth integration to pair OTC antihistamine sales with personalized symptom management and allergist referrals.

Meanwhile, regulatory scrutiny around antihistamine safety in vulnerable populations-including infants, pregnant women, and patients with cardiovascular comorbidities-is prompting updated labeling, revised dosing guidelines, and renewed focus on pharmacovigilance. As health authorities tighten safety and efficacy requirements, manufacturers must invest in robust clinical evidence, post-market surveillance, and global compliance frameworks to sustain competitiveness in both regulated and semi-regulated markets.

What Are the Factors Driving Growth in the Antihistamine Market?

The antihistamine market is expanding consistently, driven by the global rise in allergic disease burden, increasing preference for symptom-focused treatment, and the shift toward consumer-managed care. Key growth enablers include expanded OTC availability, favorable safety profiles, and ongoing innovation in delivery formats catering to patient-specific needs. The broad therapeutic reach of antihistamines across respiratory, dermatologic, gastrointestinal, and acute care settings ensures continued market relevance.

Formulation advancements, regional market penetration, and alignment with self-care trends are supporting category growth across both branded and generic segments. As demand for non-sedating, fast-acting, and long-duration antihistamines rises, manufacturers are focusing on differentiated, lifecycle-optimized portfolios to stay competitive in increasingly saturated retail channels. At the same time, digital health tools and AI-assisted allergy tracking are creating new opportunities to link antihistamines with proactive disease management.

Looking forward, the market’s evolution will be shaped by how well manufacturers address the balance between consumer accessibility, clinical efficacy, and regulatory safety. As environmental factors intensify and patient expectations evolve, could antihistamines maintain their role as the cornerstone of modern allergy and hypersensitivity symptom control?

SCOPE OF STUDY:

The report analyzes the Antihistamine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (H-1 Blockers, H-2 Blockers); Administration Route (Oral, Parenteral, Topical)); Indication (Allergies, Urticaria, Dermatitis, Other Indications); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Ajanta Pharma Limited
• Almirall S.A.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• CVS Health Corporation
• Dr. Reddy's Laboratories Ltd.
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd.
• Hetero Drugs Ltd.
• Innate Pharma S.A.
• Johnson & Johnson
• Jubilant Pharma Limited
• Menarini Group
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Olpha JSC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Antihistamine - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Allergies and Respiratory Conditions Throws the Spotlight on Antihistamine Demand
  • Expansion of OTC Medication Markets Spurs Adoption of Non-Sedating Antihistamine Formulations
  • Increased Awareness of Allergic Rhinitis and Urticaria Drives Growth in Oral and Topical Treatment Options
  • OEM Focus on Pediatric-Friendly Dosage Forms Strengthens Business Case for Family-Oriented Brands
  • Seasonal Allergy Spikes and Climate Change Bode Well for Sustained Volume Demand
  • Use in Veterinary Applications Expands Market Beyond Human Healthcare
  • Demand for Intranasal and Ophthalmic Delivery Formats Fuels Innovation in Localized Treatment Options
  • Growing Interest in Dual-Action and Extended-Release Antihistamines Improves Patient Compliance
  • Surge in E-Commerce and Direct-to-Consumer Channels Boosts Brand Accessibility and Market Penetration
  • Increased Use in Cosmetic Dermatology Supports Relief From Irritant-Driven Skin Sensitivity
  • Pharmaceutical Generics Growth Enhances Competitive Pricing and Regional Access
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Antihistamine Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Antihistamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Antihistamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Antihistamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for H-1 Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for H-1 Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for H-1 Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for H-2 Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for H-2 Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for H-2 Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Drug Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Allergies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Allergies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Allergies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Urticaria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Urticaria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Urticaria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Dermatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Dermatitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Dermatitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• JAPAN
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• CHINA
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 83: China Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• EUROPE
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Antihistamine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Antihistamine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Antihistamine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• FRANCE
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 110: France Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• GERMANY
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 146: UK Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Antihistamine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Antihistamine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Antihistamine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• INDIA
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 221: India Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Antihistamine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Antihistamine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Antihistamine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Antihistamine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Antihistamine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Antihistamine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030
• AFRICA
  • Antihistamine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Antihistamine by Product Type - H-1 Blockers and H-2 Blockers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Antihistamine by Product Type - Percentage Breakdown of Value Sales for H-1 Blockers and H-2 Blockers for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Antihistamine by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Antihistamine by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Antihistamine by Administration Route - Oral, Parenteral and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Antihistamine by Administration Route - Oral, Parenteral and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Antihistamine by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Topical for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Antihistamine by Indication - Allergies, Urticaria, Dermatitis and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Antihistamine by Indication - Percentage Breakdown of Value Sales for Allergies, Urticaria, Dermatitis and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION